Multiple sclerosis and Injection site hypersensitivity

Summary:

Injection site hypersensitivity is found among people with Multiple sclerosis, especially for people who are female, 50-59 old.

The study analyzes which people have Injection site hypersensitivity with Multiple sclerosis. It is created by eHealthMe based on reports of 109 people who have Multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Dec, 04, 2022

109 people who have Multiple Sclerosis and Injection Site Hypersensitivity are studied.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 2,068 drugs and 1,284 conditions by eHealthMe.

What is Injection site hypersensitivity?

Injection site hypersensitivity is found to be associated with 351 drugs and 187 conditions by eHealthMe.

Number of Injection site hypersensitivity in Multiple sclerosis reports submitted per year:

Would you have Injection site hypersensitivity when you have Multiple sclerosis?

Gender of people who have Multiple sclerosis and experienced Injection site hypersensitivity *:

Click here to view

Age of people who have Multiple sclerosis and experienced Injection site hypersensitivity *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Injection site hypersensitivity?

Check whether Injection site hypersensitivity is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

Related studies

Treatments, associated drugs and conditions:

Multiple sclerosis (734,914 reports)
Injection site hypersensitivity (2,143 reports)

COVID vaccines that are related to Injection site hypersensitivity:

Common drugs associated with Injection site hypersensitivity:

Enbrel: 535 reports
Humira: 312 reports
Methotrexate: 162 reports
Prednisone: 154 reports
Sandostatin: 119 reports

All the drugs that are associated with Injection site hypersensitivity:

Injection site hypersensitivity (351 drugs)

Common conditions associated with Injection site hypersensitivity:

Rheumatoid arthritis: 412 reports
Multiple sclerosis: 109 reports

All the conditions that are associated with Injection site hypersensitivity:

Injection site hypersensitivity (187 conditions)

How the study uses the data?

The study is based on Injection site hypersensitivity and Multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.